Eisai Applies For Japan Approval Of Abbott’s Meridia (Japan)
This article was originally published in PharmAsia News
Eisai says it has applied to Japan's Health Ministry to become one of the last countries in the world to market KES524, Abbott GmbH's weight-loss drug sold in the United States as Meridia (sibutramine hydrochloride). The drug, which prevents overeating, creates a sensation of being full and increases metabolic rates, already is approved in 83 other countries. Eisai sees the drug as one that can help it strengthen its domestic business, particularly since its Aricept (donepezil) Alzheimer's disease drug is set to lose U.S. patent protection in November, 2010. (Click here for more - may require paid subscription
You may also be interested in...
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.